Abstract 2989
Background
Past and recent findings indicate that adverse effects of chemotherapy influence the patients’ quality of life. The aim of this study was to investigate the implicated factors that influenced the perceived symptoms and quality of life in cancer patients during chemotherapy.
Methods
A longitudinal study was conducted in a large hospital in a major city of Northern Greece. A total of 200 cancer patients undergoing chemotherapy in cycle 2 and cycle 3 were participated in the research. Data was collected using Memorial Symptom Assessment Scale (MSAS), Functional Assessment Cancer Therapy (FACT-G) additionally with a questionnaire for the demographic and clinical characteristics. Descriptive and conductive statistical methods were applied.
Results
The vast majority of the participants were middle aged (58.94±9.94 years) men (n = 122, 61%) suffering from lung cancer (n = 98, 48%). Analysis based on the chemotherapy cycle status revealed a significant differences in several factors grouping the patients regarding their chemotherapy cycle status (cycle 2 vs cycle 3). Particularly, feeling nervous level, severity and distress of dizziness and the severity in the way of food tastes [p = 0.014, p = 0.001, p < 0.001, p < 0.001 and p = 0.030, respectively] differed statistically significantly. Moreover, multiple logistic regression analysis revealed that gender (p < 0.001) and physical well-being score (p = 0.005) affected perceived symptoms in MSAS. Furthermore, gender, occupational status, diet, type of cancer and family status influenced the overall quality of life in cycle 2 patients (p = 0.002, p < 0.001, p = 0.002, p < 0.001 and p < 0.001 respectively); however, in cycle 3 patients : gender (p = 0.003), occupational status (p < 0.001), educational status (p < 0.001) and diet (p < 0.001) were referred as the most statistically significant variables that influence the overall quality of life.
Conclusions
In conclusion, we demonstrate that adverse effects of chemotherapy in cancer patients play a critical role for the overall quality of patients’ life. Patients demographic or/ and clinicobiological characteristics seem to influence the appearance of the adverse effects.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4822 - Efficiacy of different nutritional intervention on nutritional status and quality of life for local advanced nasopharyngeal carcinoma patients: a prospective clinical trial
Presenter: Yuan-yuan Chen
Session: Poster Display session 3
Resources:
Abstract
2628 - Apatinib in treating patients with platinum-resistant or platinum-refractory recurrent or metastatic nasopharyngeal carcinoma
Presenter: Changjuan Tao
Session: Poster Display session 3
Resources:
Abstract
4887 - Impact of tumor site and adjuvant radiotherapy on survival of adenoid cystic carcinoma: a SEER database analysis
Presenter: Jason Tasoulas
Session: Poster Display session 3
Resources:
Abstract
2634 - Efficacy and safety of anlotinib for patients with recurrent and/or metastatic salivary gland carcinomas
Presenter: Wen Jiang
Session: Poster Display session 3
Resources:
Abstract
3568 - ACCURACY a phase (P) 2 trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) patients (pts) with Notch activating mutations (Notch act mut): preliminary safety and efficacy data.
Presenter: Renata Ferrarotto
Session: Poster Display session 3
Resources:
Abstract
683 - Pathologic Staging Changes in Oral Cavity Squamous Cell Carcinoma—Stage Migration and Implications for Adjuvant Treatment
Presenter: Zain Husain
Session: Poster Display session 3
Resources:
Abstract
563 - Expression of immune response biomarkers in head and neck squamous cell carcinoma (HNSCC) in irradiated area
Presenter: Carole Pflumio
Session: Poster Display session 3
Resources:
Abstract
4030 - HLA-Ligandome analysis reveals target antigens of oropharyngeal squamous cell carcinoma
Presenter: Simon Laban
Session: Poster Display session 3
Resources:
Abstract
2979 - Topographical distribution of sentinel lymph nodes in early tongue squamous cell carcinomas
Presenter: Hiroyuki Goda
Session: Poster Display session 3
Resources:
Abstract
3517 - Role of follow-up (FU) FDG-PET/CT (FU-FDG-PET/CT) in patients with locoregionally advanced squamous cell carcinoma of the head and neck (LA-HNSCC) treated with chemotherapy and radiotherapy (RT), either concurrent (CRT) or sequential (ST).
Presenter: Bert Van Den Heuvel
Session: Poster Display session 3
Resources:
Abstract